drugset
drugset / Trial / NCT00627419

A Study Evaluating the Safety and Antitumor Activity of IPI-504, in Patients With Metastatic Melanoma

NCT00627419 ↗

Phase 2 Terminated 1 enrolled Infinity Pharmaceuticals, Inc.
NaSingle-groupOpen-labelTreatment

Summary

To evaluate the antitumor activity of IPI-504 in patients with metastatic melanoma.

Timeline

Start
2008-02
Primary completion
2009-10
Completion
2009-10

Drugs

EvaluationDrugModalityDoseRoute
Subject retaspimycin Small molecule — Intravenous

Indications

metastatic melanoma